IONIS-FB-LRx, also known as RG6299, is an investigational LIgand-Conjugated Antisense (LICA) medicine designed to inhibit the production of complement factor B (FB) and the alternative complement pathway. Genetic association studies have shown that overaction of the alternative complement pathway has been associated with the development of several complement-mediated diseases, including geographic atrophy (GA), secondary to age-related macular degeneration (AMD).

About Geographic Atrophy (GA) and Age-Related Macular Degeneration (AMD)

GA associated with AMD is a progressive disease of the macula (a small part of the retina in the eye) and is the leading cause of central vision impairment in people over the age of 50 years in developed countries. The disease is characterized by progressive loss of central vision, the distortion of images and straight lines, and the presence of blurry and dark areas in the central vision.

Safety and efficacy have not been evaluated by any regulatory authorities for the indication described.

You are now leaving to visit